<DOC>
	<DOCNO>NCT00121810</DOCNO>
	<brief_summary>This 2-arm study recruit kidney transplant patient receive standard care calcineurin inhibitor ( CNIs , tacrolimus cyclosporine ) , CellCept ( 1.0-1.5 g twice daily ) corticosteroid . They either randomize continue regimen , CNI therapy discontinue replaced sirolimus therapy ( combination CellCept corticosteroid ) . The effect 2 regimen efficacy , safety kidney function evaluate . The anticipated time study treatment 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>Kidney Spare Nephron ( STN ) Study - A Study CellCept ( Mycophenolate Mofetil ) Rapamune ( Sirolimus ) Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Adult patient 1875 year age Kidney transplant 30180 day posttransplantation Receipt cyclosporine tacrolimus , CellCept , corticosteroid great 14 day prior study entry No known contraindication sirolimus Multiple organ transplant recipient secondary kidney transplant recipient Corticosteroidresistant rejection episode within 90 day prior study entry corticosteroidsensitive rejection episode within 30 day prior study entry More 1 biopsyproven episode acute rejection prior study entry Treated sirolimus study Organ transplant expect organ transplant , kidney History malignancy last 5 year ( except successfully treat localize nonmelanotic skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>